Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.57 |
| ▸ | DRD2 | P14416 | 7/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601735 | 0.82 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL7601734 | 0.82 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL7601732 | 0.82 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL30566640 | 0.81 | HTR1A (0.57) | DRD4DRD2MAPTALDH1A1HTR1A | |
| SCHEMBL1738784 | 0.81 | CHRNA7 (0.51) | DRD2DRD3MAPTALDH1A1 | |
| SCHEMBL2649519 | 0.80 | ALDH1A1 (0.58) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL7426690 | 0.80 | DRD4 (0.68) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL8311608 | 0.79 | MAPT (0.62) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL3198071 | 0.79 | HTR3E (0.61) | DRD4SIGMAR1MAPTTDP1ALDH1A1 | |
| SCHEMBL8550773 | 0.79 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-1727794-B1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PROD INC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263484-A1 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME | ZYMOGENETICS, INC. | 2011-10-27 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| US-8012969-B2 | Radiopharmaceutical for positron emission tomography; imaging brain tissue; labeled serotonin type 1B (5HT1B) receptor ligands | GE HEALTHCARE LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-8012969-B2 | Radiopharmaceutical for positron emission tomography; imaging brain tissue; labeled serotonin type 1B (5HT1B) receptor ligands | GE HEALTHCARE LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| CN-1934081-A | Novel benayl(idene)-lactam derivatives | PFIZER (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1727794-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | Pfizer Products Incorporated (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090300-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| EP-0891344-B1 | ALPHA-1 ADRENERGIC RECEPTOR ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2002-12-18 | — | — | EP | disclosed |
| EP-1229025-A1 | NOVEL QUINAZOLINE DERIVATIVES | Japan Energy Corporation (JP) | 2002-08-07 | — | — | EP | disclosed |
| EP-1205473-A1 | VESAMICOL PIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6300499-B1 | α1-adrenergic receptor antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-0891344-A1 | ALPHA 1-ADRENERGIC RECEPTOR ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997037983-A1 | α1-ADRENERGIC RECEPTOR ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | DRD4 966/4885DRD2 2415/4885DRD3 2161/4885 |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | DRD4 209/4885DRD2 69/4885DRD3 78/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | DRD4 3007/4885DRD2 1757/4885DRD3 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.